/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | BJDXBluejay Diagnostics, |
|---|---|
| Last close | $2.49close 2026-11-09 |
| Change % | +5.96%close 2026-11-09 |
| Market cap | $11Mclose 2026-11-09 |
| P/E | loss, no P/E |
| Revenue | $249040⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenues As ofFY ending 2022-12-31 Filing10-K · 0001213900-24-027305 · filed 2024-03-28 Open the filing on EDGAR →Open the XBRL payload →CiteBluejay Diagnostics, Inc. (BJDX), us-gaap:Revenues: 249,040 USD, fiscal year ended 2022-12-31. Form 10-K, accession 0001213900-24-027305, filed 2024-03-28. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001704287/us-gaap/Revenues.json |
| Rev growth (YoY) | no prior year filed |
| Net income | $-6848483⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 Filing10-K · 0001213900-26-024616 · filed 2026-03-06 Open the filing on EDGAR →Open the XBRL payload →CiteBluejay Diagnostics, Inc. (BJDX), us-gaap:NetIncomeLoss: -6,848,483 USD, fiscal year ended 2025-12-31. Form 10-K, accession 0001213900-26-024616, filed 2026-03-06. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001704287/us-gaap/NetIncomeLoss.json |
| Net margin | periods differ |
| EPS (diluted) | $-15.25⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001213900-26-024616 · filed 2026-03-06 Open the filing on EDGAR →Open the XBRL payload →CiteBluejay Diagnostics, Inc. (BJDX), us-gaap:EarningsPerShareDiluted: -15.25 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001213900-26-024616, filed 2026-03-06. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001704287/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | not scored |
| Altman Z-ScoreUNVALIDATED | not scored |
| Beneish M-ScoreUNVALIDATED | not scored |
| Next earnings | 02-28 → 03-10 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.